OSLO, Norway, May 31, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that it will present a poster describing a preclinical analysis of genetic factors that correlate with the responsiveness of non-Hodgkin's lymphoma (NHL) cell lines to Betalutin® (177Lu-lilotomab satetraxetan) at the 23rd annual meeting of the European Hematology Association (EHA) (Stockholm, Sweden, 14-17 June). This preclinical study highlights the generally promising activity of Betalutin® against diffuse large B-cell lymphoma (DLBCL) cell lines.
Abstract title: Systems biology analysis of responsiveness of non-Hodgkin lymphoma B-cell lines to CD37 targeting radioimmunotherapy
Authors: Melhus, KB et al.
Date: Friday 15 June
Time: 17:30-19:00 (CEST)
For further information, please contact:
Malene Brondberg, VP
Investor Relations and Corporate Communications
Tel/Cell: + 44-7561-431-762
Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson)
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information about the Company can be found at www.nordicnanovector.com
This information was brought to you by Cision http://news.cision.com
SOURCE Nordic Nanovector